Results 121 to 130 of about 143,360 (302)

Hematuria Management in Patients on Antiplatelet Medications After Acute Coronary Syndrome: A Review of the Current Evidence and Recommendations

Reviews in Cardiovascular Medicine
Hematuria is a frequent urological presentation, particularly in patients with significant cardiovascular comorbidities who receive dual antiplatelet therapy (DAPT) after acute coronary syndrome (ACS).
Ioannis Loufopoulos, Konstantinos Kapriniotis, Barbara Fyntanidou, Aikaterini Apostolopoulou, Athina Nasoufidou, Panagiotis Stachteas, Efstratios Karagiannidis, Efstathios Papaefstathiou   +7 more
doaj   +1 more source

UMOD Genotype and Clinical Outcomes in Heart Failure Patients Treated with Loop Diuretics: A UK Biobank Pharmacogenetic Cohort Study

Clinical Pharmacology &Therapeutics, EarlyView.
Uromodulin (UMOD) regulates tubular sodium handling and modulates NKCC2, the molecular target of loop diuretics (LD). Although UMOD variants have been associated with blood pressure and hypertension, their pharmacogenetic relevance in heart failure (HF) remains unknown.
Reinhold Kreutz, Pimrapat Gebert, Jingwen Luo, Paraskevi Tassopoulou, Juliane Bolbrinker, Antonios Douros   +5 more
wiley   +1 more source

Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor

, 2010
Margaret M Marczewski1, Marek Postula1,2, Dariusz Kosior111st Chair and Department of Cardiology, Central University Hospital, Medical University of Warsaw, Warsaw, Poland; 2Department of Experimental and Clinical Pharmacology, Medical University of ...
Margaret M Marczewski, Marek Postula, Dariusz Kosior   +2 more
core  

Enhancing Evidence Generation by Linking Randomized Clinical Trials to Real‐World Data: The INVESTED‐Medicare Linkage Study

Clinical Pharmacology &Therapeutics, EarlyView.
Real‐world evidence (RWE) derived from real‐world data (RWD) can complement randomized controlled trials (RCTs), yet the validity of RWD relative to RCT data remains insufficiently characterized. We obtained post hoc consent and linked individual participant data from the US‐based INVESTED trial (2016–2019) with Medicare fee‐for‐service claims (2012 ...
Hanseul Cho, HoJin Shin, Mehdi Najafzadeh, Brian Claggett, Janinne Ortega‐Montiel, Jun Liu, Julie M. Paik, Narlina F. Lalani, Marie C. Bradley, John Concato, Scott D. Solomon, Orly Vardeny, Elisabetta Patorno   +12 more
wiley   +1 more source

To Have and Have Not: Intrinsic Platelet Hyperreactivity?

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Marc Laine, Corinne Frere, Laurent Bonello   +2 more
doaj   +1 more source

Cangrelor Bridge for Repeat Cesarean After Third Trimester Percutaneous Coronary Intervention for Total Occlusion NSTEMI

Clinical Case Reports
Acute coronary syndrome is an uncommon but potentially life‐threatening complication in pregnancy, and dual antiplatelet therapy presents challenges in patients requiring cesarean delivery.
Vidya N. Mullangi, Sara Folk, Sneha Sharma, Gillian Belnavis, Shea Macielak, Danielle Blais, Talal Attar, Blair Suter, William H. Marshall V   +8 more
doaj   +1 more source

Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes

, 2010
Hussam M Tayeb, Adam J Nelson, Scott R Willoughby, Matthew I WorthleyCardiovascular Research Centre, Royal Adelaide Hospital and Discipline of Medicine, University of Adelaide, Adelaide, South Australia, AustraliaAbstract: Platelets play a central role ...
Scott R Willoughby, et al, Adam J Nelson, Hussam M Tayeb   +3 more
core  

Dispensing of actionable pharmacogenetic drugs among adults receiving cardiovascular disease medications in the Northern Netherlands: A serial cross‐sectional study

Clinical Pharmacology &Therapeutics, EarlyView.
The extent of pharmacogenetic (PGx) drug dispensing among Dutch adults receiving medications for cardiovascular disease (CVD) is unknown. Using the University of Groningen IADB.nl pharmacy database, we performed a serial cross‐sectional study (2019–2023) to estimate the annual prevalence of PGx drug dispensing and annual rates of initiation.
Zhuolin Zhang, Guiling Zhou, Jens H. J. Bos, Eelko Hak, Talitha Feenstra, Frank Klont   +5 more
wiley   +1 more source

Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation

Clinical Pharmacology &Therapeutics, EarlyView.
Although sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are recommended for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), concerns regarding urogenital infections persist. Therefore, we evaluated the risk of urinary tract infection (UTI) and genital tract infection (GTI) after SGLT2i initiation in this population ...
Young‐Mi Ah, Junsung Nam, Jung Wook Youn, Yun Mi Yu, Soyoung Kang   +4 more
wiley   +1 more source

Oral antiplatelet therapy for atherothrombotic disease: overview of current and emerging treatment options

, 2012
Dan J FintelBluhm Cardiovascular Institute, Feinberg School of Medicine, Northwestern University, Chicago, IL, USAAbstract: Clinical presentations of atherothrombotic vascular disease, such as acute coronary syndromes, ischemic stroke or transient ...
Fintel DJ
core